Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective

Loredana Cifaldi, Franco Locatelli, Emiliano Marasco, Lorenzo Moretta, Vito Pistoia

Research output: Contribution to journalReview article

Abstract

Natural killer (NK) cells efficiently recognize and kill tumor cells through several mechanisms including the expression of ligands for NK cell-activating receptors on target cells. Different clinical trials indicate that NK cell-based immunotherapy represents a promising antitumor treatment. However, tumors develop immune-evasion strategies, including downregulation of ligands for NK cell-activating receptors, that can negatively affect antitumor activity of NK cells, which either reside endogenously, or are adoptively transferred. Thus, restoration of the expression of NK cell-activating ligands on tumor cells represents a strategic therapeutic goal. As discussed here, various anticancer drugs can fulfill this task via different mechanisms. We envision that the combination of selected chemotherapeutic agents with NK cell adoptive transfer may represent a novel strategy for cancer immunotherapy. The well-established antitumor activity of NK cells is strictly dependent on the expression of ligands for NK cell-activating receptors on tumor cell surfaces. The molecular mechanisms underlying the upregulation of ligands for NK cell-activating receptors on tumor cells mainly depend on signaling pathways activated upon DNA damage induced by many different cytotoxic drugs. NK cell adoptive transfer in autologous or allogeneic settings represents a promising anticancer immunotherapeutic approach that has been tested in different clinical trials. The therapeutic efficacy of NK cell adoptive transfer may be dampened by downregulation of ligands for NK cell-activating receptors. A major immune-evasion mechanism adopted by most aggressive cancer cells. Many cytotoxic drugs utilized to treat cancer patients have been reported to upregulate the expression of ligands for NK cell-activating receptors in tumor cells, thus enhancing NK cell-mediated killing. Some of these drugs are excellent candidates for the design of new cancer immunotherapy protocols based on the combination of chemotherapy with allogeneic or autologous NK cell adoptive transfer.

Original languageEnglish
Pages (from-to)1156-1175
Number of pages20
JournalTrends in Molecular Medicine
Volume23
Issue number12
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Natural Killer Cells
Immunotherapy
Natural Killer Cell Receptors
Ligands
Pharmaceutical Preparations
Adoptive Transfer
Neoplasms
Up-Regulation
Down-Regulation
Clinical Trials
Tumor Escape
Immune Evasion
Combination Drug Therapy
DNA Damage
Therapeutics

Keywords

  • activating NK receptors
  • chemotherapy
  • ligands for NK cell-activating receptors
  • NK cell adoptive transfer

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs : a Perspective. / Cifaldi, Loredana; Locatelli, Franco; Marasco, Emiliano; Moretta, Lorenzo; Pistoia, Vito.

In: Trends in Molecular Medicine, Vol. 23, No. 12, 01.12.2017, p. 1156-1175.

Research output: Contribution to journalReview article

@article{cac6468aa13648878137801c84c3719c,
title = "Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective",
abstract = "Natural killer (NK) cells efficiently recognize and kill tumor cells through several mechanisms including the expression of ligands for NK cell-activating receptors on target cells. Different clinical trials indicate that NK cell-based immunotherapy represents a promising antitumor treatment. However, tumors develop immune-evasion strategies, including downregulation of ligands for NK cell-activating receptors, that can negatively affect antitumor activity of NK cells, which either reside endogenously, or are adoptively transferred. Thus, restoration of the expression of NK cell-activating ligands on tumor cells represents a strategic therapeutic goal. As discussed here, various anticancer drugs can fulfill this task via different mechanisms. We envision that the combination of selected chemotherapeutic agents with NK cell adoptive transfer may represent a novel strategy for cancer immunotherapy. The well-established antitumor activity of NK cells is strictly dependent on the expression of ligands for NK cell-activating receptors on tumor cell surfaces. The molecular mechanisms underlying the upregulation of ligands for NK cell-activating receptors on tumor cells mainly depend on signaling pathways activated upon DNA damage induced by many different cytotoxic drugs. NK cell adoptive transfer in autologous or allogeneic settings represents a promising anticancer immunotherapeutic approach that has been tested in different clinical trials. The therapeutic efficacy of NK cell adoptive transfer may be dampened by downregulation of ligands for NK cell-activating receptors. A major immune-evasion mechanism adopted by most aggressive cancer cells. Many cytotoxic drugs utilized to treat cancer patients have been reported to upregulate the expression of ligands for NK cell-activating receptors in tumor cells, thus enhancing NK cell-mediated killing. Some of these drugs are excellent candidates for the design of new cancer immunotherapy protocols based on the combination of chemotherapy with allogeneic or autologous NK cell adoptive transfer.",
keywords = "activating NK receptors, chemotherapy, ligands for NK cell-activating receptors, NK cell adoptive transfer",
author = "Loredana Cifaldi and Franco Locatelli and Emiliano Marasco and Lorenzo Moretta and Vito Pistoia",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.molmed.2017.10.002",
language = "English",
volume = "23",
pages = "1156--1175",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs

T2 - a Perspective

AU - Cifaldi, Loredana

AU - Locatelli, Franco

AU - Marasco, Emiliano

AU - Moretta, Lorenzo

AU - Pistoia, Vito

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Natural killer (NK) cells efficiently recognize and kill tumor cells through several mechanisms including the expression of ligands for NK cell-activating receptors on target cells. Different clinical trials indicate that NK cell-based immunotherapy represents a promising antitumor treatment. However, tumors develop immune-evasion strategies, including downregulation of ligands for NK cell-activating receptors, that can negatively affect antitumor activity of NK cells, which either reside endogenously, or are adoptively transferred. Thus, restoration of the expression of NK cell-activating ligands on tumor cells represents a strategic therapeutic goal. As discussed here, various anticancer drugs can fulfill this task via different mechanisms. We envision that the combination of selected chemotherapeutic agents with NK cell adoptive transfer may represent a novel strategy for cancer immunotherapy. The well-established antitumor activity of NK cells is strictly dependent on the expression of ligands for NK cell-activating receptors on tumor cell surfaces. The molecular mechanisms underlying the upregulation of ligands for NK cell-activating receptors on tumor cells mainly depend on signaling pathways activated upon DNA damage induced by many different cytotoxic drugs. NK cell adoptive transfer in autologous or allogeneic settings represents a promising anticancer immunotherapeutic approach that has been tested in different clinical trials. The therapeutic efficacy of NK cell adoptive transfer may be dampened by downregulation of ligands for NK cell-activating receptors. A major immune-evasion mechanism adopted by most aggressive cancer cells. Many cytotoxic drugs utilized to treat cancer patients have been reported to upregulate the expression of ligands for NK cell-activating receptors in tumor cells, thus enhancing NK cell-mediated killing. Some of these drugs are excellent candidates for the design of new cancer immunotherapy protocols based on the combination of chemotherapy with allogeneic or autologous NK cell adoptive transfer.

AB - Natural killer (NK) cells efficiently recognize and kill tumor cells through several mechanisms including the expression of ligands for NK cell-activating receptors on target cells. Different clinical trials indicate that NK cell-based immunotherapy represents a promising antitumor treatment. However, tumors develop immune-evasion strategies, including downregulation of ligands for NK cell-activating receptors, that can negatively affect antitumor activity of NK cells, which either reside endogenously, or are adoptively transferred. Thus, restoration of the expression of NK cell-activating ligands on tumor cells represents a strategic therapeutic goal. As discussed here, various anticancer drugs can fulfill this task via different mechanisms. We envision that the combination of selected chemotherapeutic agents with NK cell adoptive transfer may represent a novel strategy for cancer immunotherapy. The well-established antitumor activity of NK cells is strictly dependent on the expression of ligands for NK cell-activating receptors on tumor cell surfaces. The molecular mechanisms underlying the upregulation of ligands for NK cell-activating receptors on tumor cells mainly depend on signaling pathways activated upon DNA damage induced by many different cytotoxic drugs. NK cell adoptive transfer in autologous or allogeneic settings represents a promising anticancer immunotherapeutic approach that has been tested in different clinical trials. The therapeutic efficacy of NK cell adoptive transfer may be dampened by downregulation of ligands for NK cell-activating receptors. A major immune-evasion mechanism adopted by most aggressive cancer cells. Many cytotoxic drugs utilized to treat cancer patients have been reported to upregulate the expression of ligands for NK cell-activating receptors in tumor cells, thus enhancing NK cell-mediated killing. Some of these drugs are excellent candidates for the design of new cancer immunotherapy protocols based on the combination of chemotherapy with allogeneic or autologous NK cell adoptive transfer.

KW - activating NK receptors

KW - chemotherapy

KW - ligands for NK cell-activating receptors

KW - NK cell adoptive transfer

UR - http://www.scopus.com/inward/record.url?scp=85033594645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033594645&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2017.10.002

DO - 10.1016/j.molmed.2017.10.002

M3 - Review article

AN - SCOPUS:85033594645

VL - 23

SP - 1156

EP - 1175

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 12

ER -